imfinzi durvalumab | Immunotherapy for BTC, uHCC, NSCLC & ES-SCLC

Keyword	CPC	PCC	Volume	Score	Length of keyword
imfinzi durvalumab	0.12	0.3	8616	15	18
imfinzi	1.82	0.3	7763	24	7
durvalumab	0.76	0.8	8774	11	10

Keyword	CPC	PCC	Volume	Score
imfinzi durvalumab	0.06	0.3	5165	2
imfinzi durvalumab biggest company	0.77	0.1	4002	43
imfinzi durvalumab biggest controversy	1.93	0.8	1903	60
imfinzi durvalumab side effects	1.12	0.7	7443	59
imfinzi durvalumab indications	1.39	1	1890	72
imfinzi durvalumab biggest cost	1.02	1	8537	41
imfinzi durvalumab biggest comparison	0.98	0.4	6015	23
imfinzi durvalumab biggest competitor	1.39	0.6	2315	25
imfinzi durvalumab biggest customer	0.61	0.7	4512	94
imfinzi durvalumab biggest challenge	0.8	0.2	3240	46
imfinzi durvalumab biggest commercial	1.76	0.6	5749	67
imfinzi durvalumab biggest collaboration	0.95	0.9	5648	24
imfinzi durvalumab biggest clinical trial	1.34	0.2	1911	62
imfinzi durvalumab biggest competitor in cost	1.73	0.4	1172	10
imfinzi durvalumab iv	1.15	0.8	2393	92
j code for imfinzi durvalumab	1.39	0.2	8604	46
durvalumab imfinzi package insert	0.26	0.6	3549	38

Search Results related to imfinzi durvalumab on Search Engine

Immunotherapy for BTC, uHCC, NSCLC & ES-SCLC – IMFINZI® (durvalumab)
imfinzi.com

https://www.imfinzi.com/

WEBIMFINZI® (durvalumab) is an immunotherapy approved to treat patients with unresectable hepatocellular carcinoma, bile duct cancer, gallbladder cancer, unresectable Stage 3 NSCLC, Stage 4 NSCLC, and extensive-stage SCLC.

DA: 20 PA: 57 MOZ Rank: 26

IMFINZI® (durvalumab) plus chemotherapy doubled overall …
astrazeneca-us.com

https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-durvalumab-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial.html

WEBApr 16, 2024 · IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial. PUBLISHED 16 April 2024. Longest survival follow-up ever reported for immunotherapy treatment in this setting.

DA: 6 PA: 98 MOZ Rank: 40

IMFINZI® (durvalumab) - AstraZeneca US
astrazeneca-us.com

https://medicalinformation.astrazeneca-us.com/home/prescribing-information/imfinzi.html

WEBEach mL contains durvalumab, 50 mg, L-histidine (2 mg), L-histidine hydrochloride monohydrate (2.7 mg), α,α-trehalose dihydrate (104 mg), Polysorbate 80 (0.2 mg), and Water for Injection, USP.</paragraph> <paragraph>Each 120 mg vial of IMFINZI contains 120 mg of durvalumab in 2.4 mL solution.

DA: 96 PA: 63 MOZ Rank: 19

What is IMFINZI® (durvalumab) – Treatment for Unresectable …
imfinzi.com

https://www.imfinzi.com/stage-3-nsclc/about/what-is-imfinzi.html

WEBIMFINZI ® (durvalumab) is the first immunotherapy treatment approved for adults living with unresectable Stage 3 non-small cell lung cancer (NSCLC) whose disease has not progressed after CRT. CRT is a combination of chemotherapy and radiation given at …

DA: 76 PA: 59 MOZ Rank: 27

IMFINZI® (durvalumab) - Immunotherapy for Unresectable HCC, …
imfinzihcp.com

https://www.imfinzihcp.com/

WEBLearn more about IMFINZI® (durvalumab), an immunotherapy for adult patients with metastatic NSCLC, unresectable Stage III NSCLC, extensive-stage SCLC, advanced or metastatic BTC, & unresectable HCC.

DA: 26 PA: 10 MOZ Rank: 70

Durvalumab (Imfinzi) | FDA
fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/durvalumab-imfinzi

WEBOn May 1, 2017, the U.S. Food and Drug Administration granted accelerated approval to durvalumab (IMFINZI, AstraZeneca UK Limited) for the treatment of patients with locally advanced or...

DA: 98 PA: 93 MOZ Rank: 12

Durvalumab - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Durvalumab

WEBDurvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ) with the PD-1 (CD279).

DA: 53 PA: 82 MOZ Rank: 74

Imfinzi: Uses, Dosage, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/imfinzi.html

WEBJun 2, 2023 · Imfinzi (durvalumab) is a cancer medicine that works with your immune system to interfere with the growth and spread of cancer cells in the body. Imfinzi is used to treat non-small cell lung cancer (NSCLC), small cell lung cancer, or biliary tract cancer.

DA: 14 PA: 22 MOZ Rank: 18

Clinical Review - Durvalumab (Imfinzi) - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK596592/

WEBFeb 25, 2022 · Durvalumab (Imfinzi) is a fully humanized immunoglobulin G1 kappa monoclonal antibody that selectively blocks the interaction of programmed cell death 1 ligand 1 (PD-L1) with programmed cell death 1 protein (PD-1) and CD80.

DA: 66 PA: 89 MOZ Rank: 17

Imfinzi Full Prescribing Information
mayo.edu

https://ce.mayo.edu/sites/default/files/IMFINZI%C2%AE%20%28durvalumab%29%20US%20Prescribing%20Information.pdf

WEBIMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: for the treatment of adult patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (1.1)

DA: 28 PA: 87 MOZ Rank: 90